medmix intends to enter into a strategic investment in AARDEX Group
medmix (SIX: MEDX) today announced its intention to enter into a strategic investment, representing a 25% stake, in AARDEX to reinforce medmix' drug delivery business under the HaselmeierTM brand. AARDEX is a global Software as a Service (SaaS) provider of digital solutions for measuring and managing medication adherence in clinical trials.